Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)

Pas encore traduit Pas encore traduit
Catégorie Primary study
JournalEuropean Journal of Cancer Supplements
Year 2009

Cet article est inclus dans 1 Systematic review Systematic reviews (1 reference)

This article is part of the following publication threads:
Loading references information
Cet article n'a pas de résumé
Epistemonikos ID: d7b0905231f7451e8d38b99ce8d47f2bb7c66e22
First added on: Jun 07, 2022